HIV Protease Inhibitor Use during Pregnancy is Associated with Decreased Progesterone Levels, Suggesting a Potential Mechanism Contributing to Fetal Growth Restriction

Journal of Infectious Diseases

Volumn 211, Issue 1, 2015, Pages 10-18

  Papp, Eszter ^a   Mohammadi, Hakimeh ^b   Loutfy, Mona R ^c   Yudin, Mark H ^d   Murphy, Kellie E ^e   Walmsley, Sharon L ^f   Shah, Rajiv ^a   Macgillivray, Jay ^b   Silverman, Michael ^c   Serghides, Lena ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f LAKERIDGE HEALTH CORPORATION   (Canada)

Author keywords

HIV; lopinavir; low birth weight; pregnancy; progesterone; protease inhibitors; small for gestational age

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROGESTERONE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIRTH WEIGHT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FETUS GROWTH; FETUS OUTCOME; FETUS WEIGHT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INTRAUTERINE GROWTH RETARDATION; NONHUMAN; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PROGESTERONE BLOOD LEVEL; SMALL FOR DATE INFANT; TROPHOBLAST; ADULT; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; FETUS DEVELOPMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; METABOLISM; MOUSE; PREGNANCY COMPLICATIONS, INFECTIOUS; TUMOR CELL LINE; VIROLOGY;

ADULT; ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL LINE, TUMOR; FEMALE; FETAL DEVELOPMENT; FETAL GROWTH RETARDATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MICE; MICE, INBRED C57BL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PROGESTERONE; TROPHOBLASTS;

EID: 84922423692     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu393     Document Type: Conference Paper

References (35)

1. Chen JY, Ribaudo HJ, SouDa S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 2012; 206:1695-705
2. Machado ES, Hofer CB, Costa TT, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect 2009; 85:82-7
3. Ekouevi DK, Coffie PA, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cte dIvoire. AIDS 2008; 22:1815-20
4. WimalasunDera RC, Larbalestier N, Smith JH, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002; 360:1152-4
5. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature Delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21:1019-26
6. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm Delivery among HIV-infected women randomized to protease versus nucleosiDe reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011; 204:506-14
7. Newell M-L, BunDers MJ. Safety of antiretroviral drugs in pregnancy and breastfeeding for mother and child. Curr Opin HIV AIDS 2013; 8:503-9
8. Lpez M, HernnDez S, Morn C, et al. Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-utero-exposed newborn. AIDS 2012; 26:419-28
9. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature Delivery: a meta-Analysis. AIDS 2007; 21:607-15
10. Townsend C, Schulte J, Thorne C, et al. Antiretroviral therapy and preterm Delivery-A pooled analysis of Data from the United States and Europe. BJOG 2010; 117:1399-410
11. Kesho Bora Study Group, De Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171-80
12. Ross AC, Leong T, Avery A, et al. Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxiDative stress. HIV Med 2012; 13:98-106
13. Fiore S, NewellM-L, Trabattoni D, et al. Antiretroviral therapy-Associated modulation of Th1 and Th2 immune responses inHIV-infected pregnant women. J Reprod Immunol 2006; 70:143-50
14. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm Delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348:2379-85
15. Morris RK, Oliver EA, Malin G, Khan KS, Meads C. Effectiveness of interventions for the prevention of small-for-gestational age fetuses and perinatal mortality: a review of systematic reviews. Acta Obstet Gynecol Scand 2013; 92:143-51
16. Wahabi HA, Abed Althagafi NF, Elawad M, Al ZeiDan RA. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev 2011; CD005943
17. Walch KT, Huber JC. Progesterone for recurrent miscarriage: truth and Deceptions. Best Pract Res Clin Obstet Gynaecol 2008; 22: 375-89
18. SchmouDer VM, Prescott GM, Franco A, Fan-Havard P. The rebirth of progesterone in the prevention of preterm labor. Ann Pharmacother 2013; 47:527-36
19. Norwitz ER, Caughey AB. Progesterone supplementation and the prevention of preterm birth. Rev Obstet Gynecol 2011; 4:60-72
20. AnDany N, Loutfy MR. HIV protease inhibitors in pregnancy: pharmacology and clinical use. Drugs 2013; 73:229-47
21. Tseng A, Hills-Nieminen C. Drug interactions between antiretrovirals and hormonal contraceptives. Expert Opin Drug Metab Toxicol 2013; 9:559-72
22. Vogler MA, Patterson K, Kamemoto L, et al. Contraceptive efficacy of oral and transDermal hormones when co-Administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr 2010; 55:473-82
23. Simon A, Warszawski J, Kariyawasam D, et al. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA 2011; 306:70-8
24. Foisy MM, Yakiwchuk EMK, Chiu I, Singh AE. Adrenal suppression and Cushings syndrome seconDary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med 2008; 9: 389-96
25. Lorello G, la Porte C, Pilon R, Zhang G, Karnauchow T, MacPherson P. DiscorDance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma. HIV Med 2009; 10: 548-54
26. AnDerson PL, KakuDa TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17:2159-68
27. Ray JG, Sgro M, MamDani MM, et al. Birth weight curves tailored to maternal world region. J Obstet Gynaecol Can 2012; 34:159-71
28. Bahn RS, Worsham A, Speeg KV, Ascoli M, Rabin D. Characterization of steroid production in cultured human choriocarcinoma cells. J Clin Endocrinol Metab 1981; 52:447-50
29. Chougrani I, Luton D, Matheron S, ManDelbrot L, Azria E. Safety of protease inhibitors in HIV-infected pregnant women. HIV AIDS (Auckl) 2013; 5:253-62
30. Lambert JS, Else LJ, Jackson V, et al. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Med 2011; 12:166-73
31. Salas SP, Marshall G, Gutirrez BL, Rosso P. Time course of maternal plasma volume and hormonal changes in women with preeclampsia or fetal growth restriction. Hypertension 2006; 47:203-8
32. van Marthens E, Zamenhof S, Firestone C. The effect of progesterone on fetal and placental Development in normal and protein-energy-restricted rats. Nutr Metab 1979; 23:438-48
33. Wallace JM, Bourke DA, Da Silva P, Aitken RP. Influence of progesterone supplementation during the first third of pregnancy on fetal and placental growth in overnourished adolescent ewes. Reproduction 2003; 126:481-7
34. Mark PJ, Smith JT, WadDell BJ. Placental and fetal growth retarDation following partial progesterone withdrawal in rat pregnancy. Placenta 2006; 27:208-14
35. Dodd J, Jones L, Flenady V, Cincotta R, Crowther C. Prenatal administration of progesterone for preventing preterm birth in women consiDered to be at risk of preterm birth. Cochrane Database Syst Rev 2013; 7: CD004947